Literature DB >> 23063783

Cholesterol metabolism and resistance to tamoxifen.

Marc Poirot1, Sandrine Silvente-Poirot, Ralph R Weichselbaum.   

Abstract

The oncoprotein MUC-1 was shown to upregulate the transcription of genes encoding cholesterol and lipid metabolic enzymes and correlated with a resistance to Tamoxifen (Tam) despite the presence of estrogen receptor α in breast cancer tumors. The importance of this observation is supported by molecular studies on Tam suggesting two additional pharmacological targets involved in cholesterol metabolism. These observations demonstrate the potential importance of cholesterol and lipid metabolism in the pharmacology/therapeutic effects of Tam.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23063783     DOI： 10.1016/j.coph.2012.09.007

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN： 1471-4892            Impact factor:   5.547


  20 in total

1.  Clinically used selective oestrogen receptor modulators increase LDL receptor activity in primary human lymphocytes.

Authors:  F Cerrato; M E Fernández-Suárez; R Alonso; M Alonso; C Vázquez; O Pastor; P Mata; M A Lasunción; D Gómez-Coronado
Journal:  Br J Pharmacol       Date:  2015-01-08       Impact factor: 8.739

Review 2.  Metabolomic profiling of hormone-dependent cancers: a bird's eye view.

Authors:  Stacy M Lloyd; James Arnold; Arun Sreekumar
Journal:  Trends Endocrinol Metab       Date:  2015-08-01       Impact factor: 12.015

3.  Lipid Metabolism in Biliary Tract Cancer: A New Therapeutic Target?

Authors:  Daniel M Kerekes; Sajid A Khan
Journal:  Ann Surg Oncol       Date:  2022-03-03       Impact factor: 5.344

4.  Endoplasmic Reticulum Stress Protein GRP78 Modulates Lipid Metabolism to Control Drug Sensitivity and Antitumor Immunity in Breast Cancer.

Authors:  Katherine L Cook; David R Soto-Pantoja; Pamela A G Clarke; M Idalia Cruz; Alan Zwart; Anni Wärri; Leena Hilakivi-Clarke; David D Roberts; Robert Clarke
Journal:  Cancer Res       Date:  2016-10-01       Impact factor: 12.701

5.  Selective changes in cholesterol metabolite levels in plasma of breast cancer patients after tumor removal.

Authors:  Pavel Soucek; David Vrana; Yune-Fang Ueng; Shouzou Wei; Renata Kozevnikovova; Frederick Peter Guengerich
Journal:  Clin Chem Lab Med       Date:  2018-02-23       Impact factor: 8.490

6.  Clinically used selective estrogen receptor modulators affect different steps of macrophage-specific reverse cholesterol transport.

Authors:  María E Fernández-Suárez; Joan C Escolà-Gil; Oscar Pastor; Alberto Dávalos; Francisco Blanco-Vaca; Miguel A Lasunción; Javier Martínez-Botas; Diego Gómez-Coronado
Journal:  Sci Rep       Date:  2016-09-07       Impact factor: 4.379

7.  Cholesterol-Induced Metabolic Reprogramming in Breast Cancer Cells Is Mediated via the ERRα Pathway.

Authors:  Faegheh Ghanbari; Anne-Marie Fortier; Morag Park; Anie Philip
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

8.  Dendrogenin A arises from cholesterol and histamine metabolism and shows cell differentiation and anti-tumour properties.

Authors:  Philippe de Medina; Michael R Paillasse; Gregory Segala; Maud Voisin; Loubna Mhamdi; Florence Dalenc; Magali Lacroix-Triki; Thomas Filleron; Frederic Pont; Talal Al Saati; Christophe Morisseau; Bruce D Hammock; Sandrine Silvente-Poirot; Marc Poirot
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

9.  Identification of a novel luminal molecular subtype of breast cancer.

Authors:  Anna Dvorkin-Gheva; John A Hassell
Journal:  PLoS One       Date:  2014-07-30       Impact factor: 3.240

10.  Molecular and Biochemical Analysis of the Estrogenic and Proliferative Properties of Vitamin E Compounds.

Authors:  Farid Khallouki; Philippe de Medina; Stéphanie Caze-Subra; Kerstin Bystricky; Patrick Balaguer; Marc Poirot; Sandrine Silvente-Poirot
Journal:  Front Oncol       Date:  2016-01-05       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.